[Extrabronchial effects of Bronchodilat in patients with asthma and chronic asthmatic bronchitis].
Published in Gruzlica i choroby pluc; tuberculosis et pneumonologia
Angiotensin converting enzyme inhibition in heart failure.
Published in British journal of clinical pharmacology
Captopril, the first orally effective converting enzyme inhibitor, was administered to 14 patients with chronic heart failure for 6 week periods, in a double-blind crossover comparison with placebo. Captopril improved symptoms and exercise performance, while left ventricular internal dimensions were reduced. The fall in blood pressure induced by ca...
The role of digitalis in the future.
Published in British journal of clinical pharmacology
Cardiac glycosides exert an acute positive inotropic effect on the normal and failing heart. Recent evidence establishes that the positive inotropic effect is maintained over several months in many patients. The effectiveness of long-term treatment with cardiac glycosides in relieving symptoms is less certain; only a small subset of patients benefi...
Enalapril in heart failure.
Published in British journal of clinical pharmacology
Serum MK-422 and plasma angiotensin converting enzyme activity were measured during the introduction of enalapril therapy in eight patients with heart failure. In a second study of 16 patients, we recorded exercise tolerance, clinical status and haemodynamics before and after 12 weeks of placebo or enalapril treatment. Increasing doses of enalapril...
Drug therapy of chronic heart failure.
Published in Cardiovascular drugs and therapy
Chronic heart failure is an irremediable terminal syndrome. The inability of the heart to pump sufficient blood to meet the demands of metabolically active tissues is aggravated by reflex increases in peripheral vasoconstriction induced by the sympathoadrenal and renin-angiotensin-aldosterone systems. Vasoconstriction is partially attenuated by atr...
Current therapy of acute heart failure.
Published in Cardiovascular drugs and therapy
Acute heart failure involves various pathophysiological mechanisms among which primary reduction of myocardial contractility due to acute myocardial infarction, cardiomyopathy, and after open heart surgery are the most common. Therapy should be as causally related as possible. In patients with mechanical defects such as rupture of the interventricu...
The pathophysiologic profile of congestive heart failure.
Published in Cardiovascular drugs and therapy
Congestive heart failure (CHF) evolves either from an excessive workload or in response to loss of myocardium, both of which cause cardiac hypertrophy, increased cardiac pressure, and loss of functional reserve. Nearly 60% of patients in heart failure present with ischemic cardiomyopathy, which in its chronic form exhibits biventricular dilatation,...
The effects of age, sex and treatment with xamoterol on exercise capacity in patients with heart failure.
Published in British journal of clinical pharmacology
The influence of age, sex and xamoterol treatment on exercise capacity has been investigated in 705 heart failure patients who took part in a multicentre, placebo-controlled study. Regression analysis suggests that although less than 20% of the total variation in exercise capacity between patients is explained by these factors, useful information m...
The management of heart failure and the scope for new therapies: what role for xamoterol?
Published in British journal of clinical pharmacology
1. Current therapy of heart failure leaves much to be desired. Not all patients respond, and many agents lose their effects with time. 2. Newer agents may be effective but toxic, and some which have a beneficial action when given intravenously have proved disappointing when used orally. 3. The value of digoxin in patients in sinus rhythm is open to...
Xamoterol, a beta 1-adrenoceptor partial agonist: review of the clinical efficacy in heart failure.
Published in British journal of clinical pharmacology
1. Xamoterol (Corwin, Carwin, Corwil, Xamtol, ICI 118,587), a beta 1-adrenoceptor partial agonist, improves both systolic and diastolic function in heart failure patients. 2. Double-blind, randomised studies comparing xamoterol with placebo showed that the beneficial haemodynamic effects of xamoterol produced significant improvements in exercise ca...
